A Phase 3 interventional study of Dexamethasone in Crohn's Disease, sponsored by Quince Therapeutics S.p.A.. Terminated at 8 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-03.
Sponsored by Quince Therapeutics S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Crohn Disease with a site in Italy — 54 open to participants now, 78 under way, 29 of them phase 3. Crohn Disease · Italy.
Among the 205 studies in Crohn Disease with a site in Italy, this one is the 127th largest by enrollment of the 163 interventional ones that give a count, is the only one that started in 2009, is one of 78 in phase 3, and was the 19th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →54 of the 205 studies in Crohn Disease with a site in Italy are open now. Recruiting first, the newest first:
University of Padova · Sites in Italy
Ages 18–75
Janssen Research & Development, LLC · Sites in Italy, United States, Argentina and 27 more countries
Ages 18+
San Giovanni Addolorata Hospital · Sites in Italy
Ages 18–85
Eli Lilly and Company · Sites in Italy, United States, Belgium and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in Italy, United States, Belgium and 7 more countries
Ages 18–80
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 49 · Phase 3 82 · Phase 4 7
First in 2001; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 187 across the 163 interventional studies, 200 across the 42 observational. Of the 107 that completed or were terminated, 68 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
139 of 205 have an industry lead sponsor. The 10 most frequent:
Quince Therapeutics S.p.A. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Quince Therapeutics S.p.A. has 1 study filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
21 of the studies in Crohn Disease with a site in Italy that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
Add all 21 to your calendar (.ics) → With an account.
Among the 205 studies in Crohn Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary objective:
Assessment of the efficacy of EryDex vs PLACEBO in maintaining patients with steroid-dependent Crohn's disease in clinical remission throughout 12 months without oral steroids.
Secondary objectives:
This was a multicenter, randomized, double-blind, PLACEBO-controlled, parallel-group study comparing EryDex versus PLACEBO. Patients with steroid-dependent Crohn's disease were enrolled and randomized to undergo 12 infusions of intraerythrocyte dexamethasone (EryDex), or PLACEBO. A balanced (1:1) randomization between the two treatment groups (EryDex / PLACEBO) was employed.
At the time of randomization, study patients were stratified at each study site according to their previous therapy with AZT/6MP/MTX (never treated with AZT/6MP/MTX or intolerant/resistant to the therapy with AZT/6MP/MTX). The treatment was planned to be performed with 12 monthly infusions of EryDex or PLACEBO.
Patients were followed-up after completion of the treatment for 6 months in patients regularly completing the study and 3 months in patients discontinuing from the study prematurely. The evaluation of the primary and secondary objectives was to be done at the 12th month of study (one month after the last study drug infusion), or upon relapse.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Severe concomitant diseases such as :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ery-dex (dexamethasone sodium phosphate)is administered as intra-erythrocyte drug at monthly interval
Drug: Dexamethasone
placebo comparator (sodium chloride instead of dexamethasone sodium phosphate) is administered in infusion at monthly interval.
Drug: Dexamethasone
500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
Also known as: Ery-dex
Percentage of Patients Maintaining Steroids-free Clinical Remission (CDAI<150) Without Surgery for 12 Months
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) \< 150. A therapy failure was considered to have occurred in patients with a CDAI score over 150 for \> 2 weeks and/or the need for systemic steroids (with / without surgery). Hence, the higher the index, the worse the outcome.
Time frame: after 12 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
This evaluation of safety was made by the comparison of treatment emergent adverse events (TEAE). Treatment emergent adverse events (TEAE) are undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment.
Time frame: after 12 months
Percentage of Patients Interrupting the Study Because of Adverse Events
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: after 12 months
Duration of the Period of Steroid-free Clinical Remission
The mean time between the end of the steroid therapy and a confirmed relapse of the disease.
Time frame: From end of the steroid therapy to relapse, up to 545 days
Dosing of Serum Cortisol
Levels of serum cortisol were measured at baseline and following Adrenocorticotropic Hormone (ACTH) trigger.
Time frame: At Baseline and at the end of the study (18 months)
There were 63 patients enrolled into the screening phase at 10 sites; of these, 51 patients (representing the Safety population) were randomized at 9 sites.
| Milestone | Ery-dex | Placebo |
|---|---|---|
| Started | 28 | 23 |
| Completed | 5 | 2 |
| Not completed | 23 | 21 |
| Withdrew: Fragile vein | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Therapy failure and/or crohn's surgery | 13 | 16 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Consent withdrawn | 1 | 1 |
| Withdrew: Premature closure of the study | 4 | 2 |
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) \< 150. A therapy failure was considered to have occurred in patients with a CDAI score over 150 for \> 2 weeks and/or the need for systemic steroids (with / without surgery). Hence, the higher the index, the worse the outcome.
| Participants | Ery-dex | Placebo |
|---|---|---|
| Percentage of Patients Maintaining Steroids-free Clinical Remission (CDAI<150) Without Surgery for 12 Months | 5 | 2 |
This evaluation of safety was made by the comparison of treatment emergent adverse events (TEAE). Treatment emergent adverse events (TEAE) are undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment.
| Participants | Ery-dex | Placebo |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 13 | 6 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
| Participants | Ery-dex | Placebo |
|---|---|---|
| Percentage of Patients Interrupting the Study Because of Adverse Events | 2 | 1 |
The mean time between the end of the steroid therapy and a confirmed relapse of the disease.
| Days | Ery-dex | Placebo |
|---|---|---|
| Duration of the Period of Steroid-free Clinical Remission | 55.3 ± 73.2 | 84.9 ± 72.9 |
Levels of serum cortisol were measured at baseline and following Adrenocorticotropic Hormone (ACTH) trigger.
| μg/dl | Ery-dex | Placebo |
|---|---|---|
| At Baseline - before ACTH | 6.8 ± 4.6 | 7.1 ± 6.2 |
| At the end of the study - before ACTH | 11.3 ± 8.6 | 6.4 ± 5.4 |
| At baseline - after ACTH | 10.3 ± 7.6 | 11.0 ± 6.5 |
| At the end of the study - after ACTH | 18.4 ± 4.7 | 12.7 ± 7.6 |
Collected over Adverse events were collected from Visit 1 ( Day 15) up to Visit 15 (Day 600). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ery-dex | 0/28 (0%) | 6/28 (21.4%) | 19/28 (67.9%) |
| Placebo | 1/23 (4.3%) | 4/23 (17.4%) | 16/23 (69.6%) |
| Event | Ery-dex | Placebo |
|---|---|---|
| SubileusGastrointestinal disorders | 1/28 | 3/23 |
| Crohn's diseaseGastrointestinal disorders | 2/28 | 0/23 |
| Staphylococcal infectionInfections and infestations | 0/28 | 1/23 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/28 | 0/23 |
| Intestinal obstructionGastrointestinal disorders | 1/28 | 0/23 |
| Spinal fractureInjury, poisoning and procedural complications | 1/28 | 0/23 |
| Event | Ery-dex | Placebo |
|---|---|---|
| AstheniaGeneral disorders | 3/28 | 4/23 |
| CushingoidEndocrine disorders | 4/28 | 0/23 |
| SubileusGastrointestinal disorders | 2/28 | 3/23 |
| HeadacheNervous system disorders | 0/28 | 3/23 |
| InfluenzaRespiratory, thoracic and mediastinal disorders | 3/28 | 3/23 |
| NauseaGastrointestinal disorders | 3/28 | 2/23 |
| IrritabilityGeneral disorders | 3/28 | 2/23 |
| InsomniaPsychiatric disorders | 3/28 | 2/23 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/28 | 2/23 |
| VomitingGastrointestinal disorders | 1/28 | 2/23 |
| Age, Categorical(Participants) | Ery-dex | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 24 | 20 | 44 |
| >=65 years | 4 | 3 | 7 |
| Age, Continuous(years) | Ery-dex | Placebo | Total |
|---|---|---|---|
| Mean | 47.3 ± 14.9 | 43.4 ± 12.5 | 45.5 ± 13.9 |
| Sex: Female, Male(Participants) | Ery-dex | Placebo | Total |
|---|---|---|---|
| Female | 20 | 7 | 27 |
| Male | 8 | 16 | 24 |
| Race (NIH/OMB)(Participants) | Ery-dex | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 28 | 23 | 51 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Ery-dex | Placebo | Total |
|---|---|---|---|
| Romania | 1 | 0 | 1 |
| Italy | 27 | 22 | 49 |
| Spain | 0 | 1 | 1 |
Ran from Jun 2009 to primary completion in Dec 2011, 30 months.
Results were first posted in Jun 2024, 12 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
Quince Therapeutics S.p.A.